Nevro (NYSE: NVRO) reported Q1 EPS of ($0.70), $0.35 better than the analyst estimate of ($1.05). Revenue for the quarter came in at $101.9 million versus the consensus estimate of $97.93 million.

GUIDANCE:

Nevro sees Q2 2024 revenue of $106-108 million, versus the consensus of $111.4 million.
Adjusted EBITDA to be in the range of negative $3.5 million to negative $2.5 million.

Nevro continues to expect its full-year 2024 worldwide revenue to be in the range of approximately $435 million to $445 million, versus the consensus of $441.1 million.

Nevro is raising its adjusted EBITDA guidance for the full-year 2024 to a range of negative $5 million to positive $2 million from its previous guidance range of negative $14 million to negative $8 million. Nevro\'s revised expectations for full-year 2024 adjusted EBITDA guidance reflects the better-than-anticipated adjusted EBITDA in the first quarter of 2024, approximately $10 million in incremental savings in 2024 as a result of the restructuring, and its outlook for the remainder of this year. The company noted that it expects $4 million to $5 million in restructuring charges in the second quarter of 2024.

For earnings history and earnings-related data on Nevro (NVRO) click here.